Refractory Medulloblastoma Recruiting Phase 2 Trials for Ivosidenib (DB14568)

IndicationStatusPhase
DBCOND0105102 (Refractory Medulloblastoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04195555Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Treatment